An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin, and their 13-dihydro metabolites in human plasma

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 367-375

  Fogli, Stefano ^a   Danesi, Romano ^a   Innocenti, Federico ^a   Di Paolo, Antonello ^a   Bocci, Guido ^a   Barbara, Cecilia ^a   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

13 Dihydro metabolites; Anthracyclines; Drug monitoring; HPLC; Pharmacokinetics

Indexed keywords

CHLOROFORM; DAUNORUBICIN; DOXORUBICIN; DRUG METABOLITE; EPIRUBICIN; HEPTANOL; IDARUBICIN; PHOSPHORIC ACID;

ACCURACY; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG MONITORING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REGRESSION ANALYSIS; SIGNAL NOISE RATIO;

ANTIBIOTICS, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DAUNORUBICIN; DOXORUBICIN; DRUG MONITORING; EPIRUBICIN; HUMANS; IDARUBICIN; LINEAR MODELS; MOLECULAR STRUCTURE; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0032967418     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00022     Document Type: Article

References (27)

1. Hortobágyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs 1997;54(suppl 4):1-7.
2. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86.
3. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southestern Cancer Study Group study. J Clin Oncol 1992;10:1103-11.
4. Coukell AJ, Faulds D. Epirubicin: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer. Drugs 1997;53:453-82.
5. Allen A. The cardiotoxicity of chemotherapeutic drugs. Semin Oncol 1992;19:529-42.
6. Desoize B, Robert J. Individual dose adaptation of anticancer drug. Eur J Cancer 1994;30A:844-51.
7. Schleyer E, Kuhn S, Ruhrs H, et al. Oral idarubicin pharmacokinetics correlation of through level with idarubicin area under the curve. Leukemia 1996;10:707-12.
8. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 1992;29:391-5.
9. Camaggi CM, Comparsi R, Strocchi E, Testoni F, Pannuti F. HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol 1988;21: 216-20.
10. Camaggi CM, Carisi P, Strocchi E, Pannuti F. High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol 1992; 30:303-6.
11. Jacquet JM, Galtir M, Bressolle F, Jourdan J. A sensitive and reproducible HPLC assay for doxorubicin and pirarubicin. J Pharm Biomed Anal 1992;10:343-8.
12. Andersen A, Warren DJ, Slordal L. A sensitive and simple high-performance liquid chromatographic method for the determination of doxorubicin and its metabolites in plasma. Ther Drug Monit 1993;15:455-61.
13. de Jong J, Maessen PA, Akkerdaas A, Cheung SF, Pinedo HM, van der Vijgh WJ. Sensitive method for determination of daunorubicin and its known metabolites in plasma and hearth by high-performance liquid chromatography with fluorescence detection. J Chromalogr A 1990;529:359-68.
14. Barken IK, Crawford SM, Fell AF. Determination of plasma concentration of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy. J Chromatogr B Biomed Appl 1996;681:323-9.
15. Gianni L, Vigano L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997;15:1906-15.
16. Dodds HM, Walpole ET, Rivory LP, Strong RW, Pond SM. Disposition of epirubicin after intraarterial administration in Lipiodol to patients with hepatocellular carcinoma. Ther Drug Monit 1996; 18:537-43.
17. Snyder LR, Kirkland JJ, Glach JL, eds. Practical HPLC method development. New York: Wiley J & Sons, Inc, 1997.
18. Bachur NR. Adriamycin-daunorubicin cellular pharmacodynamics. Biochem Pharmacol 1974;23(suppl 2):207-16.
19. Bachur NR, Gordon SL, Gee MV. Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 1977;13:901-10.
20. Minotti G, Cavaliere AF, Mordente A, et al. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity. J Clin Invest 1995;95:1595-605.
21. Olson RD, Mushlin PS, Brenner DE, et al. Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol. Proc Natl Acad Sci USA 1988;85:3585-9.
22. Mushlin PS, Cusack BJ, Boucek RJ Jr, Andrejuk T, Li X, Olson RD. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 1993;110:975-82.
23. Holmes FA, Madden T, Newman RA, et al. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1996;14:2713-21.
24. Berg LB, Cowan KH, Balis FM, et al. Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 1994;86:143-5.
25. Embree L, Gelmon KA, Mayer LD, et al. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. J Pharm Sci 1993;82:627-34.
26. Camaggi CM, Strocchi E, Carisi P, Martoni A, Melotti B, Pannuti F. Epirubicin metabolism and pharmacokinetics after conventional and high dose intravenous administration: a cross-over study. Cancer Chemother Pharmacol 1993;32:301-9.
27. Moro E, Bellotti V, Jannuzzo MJ, Stegnjaich S, Valzelli G. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative. J Chromatogr B Biomed Appl 1983;274: 281-7.